Why do we need to eradicate pathogens in respiratory tract infections?

International Journal of Infectious Diseases

Volumn 7, Issue SUPPL. 1, 2003, Pages

  Garau, Javier ^a  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; COTRIMOXAZOLE; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BLOOD CULTURE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; ECONOMIC ASPECT; ERADICATION THERAPY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LOBAR PNEUMONIA; MINIMUM INHIBITORY CONCENTRATION; OTITIS MEDIA; PENICILLIN RESISTANCE; PHARMACODYNAMICS; RESPIRATORY TRACT INFECTION; SINUSITIS; STREPTOCOCCUS PNEUMONIA; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 0037346073     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(03)90065-8     Document Type: Conference Paper

References (38)

1. Ball P, Baquero F, Cars O, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002; 49:31-40.
2. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in the respiratory tract is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47:129-140.
3. Dagan R, Leibovitz E, Greenberg D, Yagupsky P, Fliss DM, Leiberman A. Early eradication of pathogens from middle ear fluid during antibiotic treatment is associated with improved clinical outcome. Pediatr Infect Dis J 1998; 17:776-782.
4. Beghi G, Berni F, Carratu L, et al. Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis. J Chemother 1995; 7:146-152.
5. Pechère J-C. Modeling and predicting clinical outcomes of antibiotic therapy. Infect Med 1998; 15(suppl E):46-50.
6. Alexander Project 2001. Data on file, GlaxoSmithKline.
7. Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000; 44:43-50.
8. Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999; 29:321-327.
9. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223-229.
10. Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30:520-528.
11. Azoulay-Dupuis E, Rieux V, Muffat-Joly M, et al. Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice. Antimicrob Agents Chemother 2000; 44:1575-1577.
12. Moroney JF, Fiore AE, Harrison LH, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001; 33:797-805.
13. Quach C, Weiss K, Moore D, Rubin R, Restieri C. Clinical presentation, outcome, cost and risk factors associated with invasive Streptococcus pneumoniae (Sp) infections in a pediatric population: a case-control study [Abstract 1862]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. Washington, DC: American Society for Microbiology, 2000:463.
14. Bédos JP, Chardon H, Jehl F, et al. Impact of penicillin resistance in community-acquired pneumococcal pneumonia (CAPP) in adult hospitalized patients: findings of a French national prospective survey [Abstract 851]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA. Washington, DC: American Society for Microbiology, 2001:447.
15. Bryan CS, Talwani R, Stinson MS. Penicillin dosing for pneumococcal pneumonia. Chest 1997; 112:1657-1664.
16. Sanchez C, Armengol R, Lite J, Mir I, Garau J. Penicillin-resistant pneumococci and community-acquired pneumonia. Lancet 1992; 339:988.
17. Garau J, Lonks JR, Gomez L, Xercavins M, Medeiros AA. Failure of macrolide therapy in patients with bacteremia due to macrolide resistant Streptococcus pneumoniae [Abstract 709]. In: 5th International Conference on Macrolides, Azalides and Streptogramins, Sevilla, Spain, 2000.
18. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2001; 31:1008-1011.
19. Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multi-drug resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000; 31:613-615.
20. Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 2000; 118:1839-1840.
21. Deligne B, Turgeon PL, Fleury C, et al. Are macrolides still appropriate for empiric therapy of community-acquired pneumococcal pneumonia [Abstract 1849]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA. Washington, DC: American Society for Microbiology, 2001:472.
22. Lonks JR, Garau J, Gomez L, Xercavins M, De Echaguen AO, Medeiros AA. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35:556-564.
23. Musher DM, Dowell SF, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:630-631.
24. Tait-Kamradr A, Davies T, Appelbaum PC, et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000; 44:3395-3401.
25. Lee BL, Padula AM, Kimbrough RC, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991; 325:520-521.
26. Righter J. Pneumococcal meningitis during intravenous ciprofloxacin therapy. Am J Med 1990; 88:548.
27. Saito H, Kajita M, Shimokata K. Overwhelming pneumococcal pneumonia in a patient receiving ofloxacin for antimicrobial prophylaxis. Jpn J Med 1990; 29:89-90.
28. Kuehnert MJ, Nolte FS, Perlino CA. Fluoroquinolone resistance in Streptococcus pneumoniae. Ann Intern Med 1999; 131:312-313.
29. Fishman NO, Suh B, Weigel LM, et al. Three levofloxacin treatment failures of pneumococcal respiratory tract infections [Abstract 825]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA. Washington, DC: American Society for Microbiology, 1999:111.
30. Empey PE, Jennings HR, Thornton AC, Rapp RP, Evans ME. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacother 2001; 35:687-690.
31. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:747-750.
32. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactam. Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279:365-370.
33. Schrag SJ, Peña C, Fernandez J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage. JAMA 2001; 286:49-56.
34. Ghaffar F, Muniz LS, Katz K, et al. Effects of large doses of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, nonpneumococcal α-hemolytic streptococci, and Staphylococcus aureus in children with acute otitis media. Clin Infect Dis 2002; 34:1301-1309.
35. Ghaffar F, Muniz LS, Katz K, et al. Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media. Clin Infect Dis 2000; 31:875-880.
36. Boles M, Harbarth S, Chinn C, Carmeli Y. Assessing the cost implications of microbiological sensitivity to antibiotic treatment in lower respiratory tract infections (LRTI) [Abstract 2129]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. Washington, DC: American Society for Microbiology, 2000:509.
37. Bertran MJ, Trilla A, Codina C, Carne X, Ribas J, Asenjo MA. Analysis of the cost-effectiveness relationship in the empirical treatment of patients with infections of the lower respiratory tract acquired in the community. Enferm Infecc Microbiol Clin 2000; 18:445-451.
38. Boyter AC, Davey PG, Hudson SA, Clark RA, Lipworth BJ. Evaluation of an antibiotic prescribing protocol for the treatment of acute exacerbations of chronic obstructive airways disease in a hospital respiratory unit. J Antimicrob Chemother 1995; 36:403-409.